Cat. No. 2850
Chemical Name: 6,11-Dihydrobenzothiopyrano[4,3-
Biological ActivitySpecific, non-competitve 15-lipoxygenase (15-LOX) inhibitor (Ki = 197nM) that has no demonstrable effect on 5-LOX, 12-LOX, COX-1 or COX-2 (IC50 = 0.54 μM for 15-LOX in rabbit reticulocytes). Lacks non-specific antioxidant properties and prevents atherogenesis via regulation of monocyte-macrophage enrichment in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Sordillo et al (2005) Enhanced 15-HPETE production during oxidant stress induces apoptosis of endothelial cells. Prostaglandins Other Lipid Mediat. 76 19. PMID: 15967159.
Bocan et al (1998) A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis 136 203. PMID: 9543090.
Sendobry et al (1997) Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br.J.Pharmacol. 120 1199. PMID: 9105693.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products. Selected citations for PD 146176 include:
Ruparel et al (2012) Plasticity of cytochrome P450 isozyme expression in rat trigeminal ganglia neurons during inflammation. Cancer Res 153 2031. PMID: 22633978.
Do you know of a great paper that uses PD 146176 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: PD 146176, supplier, Selective, 15-lipoxygenase, inhibitors, inhibits, Oxygenases, Oxidases, PD146176, 15-LOX, Tocris Bioscience, Lipoxygenase Inhibitor products
Find multiple products by catalog number
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.